Streetbeat News

Stock Prices

BAC

JPM

XLF

JPMorgan Chase & Co (JPM) and Bank of America Corp (BAC) reported Q4 2023 earnings, with JPM outperforming BAC. JPM benefited from new deposits, a low-cost acquisition, and record profits, while BAC faced challenges due to interest rate sensitivity and unrealized losses on long-term securities. With expected rate cuts in 2024, analysts see more upside in BAC stock (11.58%) than JPM (9.66%), despite BAC's risks. The Financial Select Sector SPDR Fund (XLF) gained over 5% in 2023.

Portfolio Pulse from Surbhi Jain

January 12, 2024 | 3:48 pm

FIVN

Piper Sandler analyst James Fish has maintained an Overweight rating on Five9 (NASDAQ:FIVN) and increased the price target from $84 to $86.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:48 pm

FFNW

Piper Sandler analyst Andrew Liesch has maintained an Overweight rating on First Financial Northwest (NASDAQ: FFNW) and increased the price target from $14 to $23.5.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:46 pm

ALK

DAL

LUV

SKYW

UAL

Over 1,600 flights were canceled in the U.S. due to a severe winter storm causing power outages and disruptions. Delta Air Lines, Southwest Airlines, SkyWest, and United have all experienced significant cancellations and delays. United is also dealing with regulatory issues regarding the Boeing 737 MAX 9 jets after an incident with an Alaska Air Group flight. Shares of Delta Air Lines dropped 8.2% amid these disruptions.

Portfolio Pulse from Shivani Kumaresan

January 12, 2024 | 3:45 pm

SPY

USO

The White House, through spokesperson John Kirby, has announced that the U.S. is currently assessing the impacts of recent airstrikes on Iran-backed Houthi forces. The situation is being closely monitored to understand the repercussions of these military actions.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:44 pm

MDAI

Spectral AI, Inc. (NASDAQ:MDAI) stock is trading higher after the company announced the enrollment of the first patient in a study to validate its DeepView AI technology for burn injuries. This study is the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025. The company has been using $251 million of non-dilutive government funding since 2019 to validate DeepView for burn indication and is also advancing other clinical indications. The stock experienced heavy trading volume, with over 15.3 million shares traded compared to its 100-day average volume of just under 972,000 shares.

Portfolio Pulse from Erica Kollmann

January 12, 2024 | 3:43 pm

Goldman Sachs (GS) is anticipated to release Q4 earnings on Jan. 16, 2023, with expected earnings of $3.41 per share on revenue of $10.80 billion. UBS and JPMorgan raised their price targets for GS to $440 and $421, respectively. GS Asset Management closed the West Street Life Sciences I fund above its target with $650 million in equity commitments. GS has a dividend yield of 2.90%, with a quarterly dividend of $2.75 per share. To earn $500 monthly in dividends, an investor would need 545 shares, valued at approximately $206,964. GS shares fell 0.6% to close at $379.75 recently.

Portfolio Pulse from Avi Kapoor

January 12, 2024 | 3:43 pm

ENPH

Piper Sandler analyst Kashy Harrison has maintained a Neutral rating on Enphase Energy (NASDAQ:ENPH) but has reduced the price target from $120 to $117.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 3:39 pm

AAL

DAL

UAL

Delta Air Lines, Inc. (NYSE:DAL) reported Q4 FY23 results with operating revenue growth of 5.9% Y/Y to $14.22 billion and adjusted EPS of $1.28, beating consensus. Despite this, DAL shares fell 7.9%. Other stocks also moved lower, including United Airlines (NASDAQ:UAL) and American Airlines (NASDAQ:AAL), which dropped in sympathy with Delta. Various other stocks across different sectors also recorded losses on Friday.

Portfolio Pulse from Avi Kapoor

January 12, 2024 | 3:39 pm

BFLY

Butterfly Network Inc (NYSE:BFLY) shares rose after announcing expectations to exceed FY23 revenue and adjusted EBITDA loss guidance, with anticipated revenues of at least $64 million. The company also received FDA clearance for its new handheld ultrasound system, Butterfly iQ3, set to launch in Q1 2024. The positive financial outlook and product advancement have led to a 7.34% increase in BFLY shares in premarket trading.

Portfolio Pulse from Lekha Gupta

January 12, 2024 | 3:32 pm